Mechanism, potency and restriction of anti-CTLA-4 and anti-PD-1 immunotherapies in cancer

Abstract

Melanoma and some other cancers identified with high fatality rates which are highly radio and chemotherapy resistant yet may be very immunogenic. These factors have showed to a current surge in research into therapies focusing to boost anticancer immune responses in patients. Beside these therapies, neutralizing antibodies targeting the immune checkpoints cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are being approached as specifically successful. Although, the most of advanced stage melanoma patients ignore, and the search for the “magic bullet” to treat the disease continuously. Anti-PD-1/PD-L1 and anti-CTLA-4 antibodies are the two types of checkpoint inhibitors currently available to melanoma and other cancer patients.